Skip to content

Study · Randomized controlled trial · n = 68 · 1996

12 results

The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender.

Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rośen T, Thorén M, Bengtsson BA

The Journal of clinical endocrinology and metabolism1 Apr 1996Cited by 111 (Europe PMC)

PMID8636370 (opens in a new tab)DOI10.1210/jcem.81.4.8636370 (opens in a new tab)PepBankPUB-08636370
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH increased serum IGF-I versus placebo (P < 0.001).

    In plain wordsIn GH-deficient adults, GH increased serum IGF-I compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseSerum IGF-I
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the placebo control period, serum IGF-I,LBM, and TBW increased (P < 0.001), whereas BF decreased (P < 0.001) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH increased lean body mass versus placebo (P < 0.001).

    In plain wordsIn GH-deficient adults, GH increased lean body mass compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the placebo control period, serum IGF-I,LBM, and TBW increased (P < 0.001), whereas BF decreased (P < 0.001) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH increased total body water versus placebo (P < 0.001).

    In plain wordsIn GH-deficient adults, GH increased total body water compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseTotal body water
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the placebo control period, serum IGF-I,LBM, and TBW increased (P < 0.001), whereas BF decreased (P < 0.001) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH decreased body fat versus placebo (P < 0.001).

    In plain wordsIn GH-deficient adults, GH decreased body fat compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseBody fat
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the placebo control period, serum IGF-I,LBM, and TBW increased (P < 0.001), whereas BF decreased (P < 0.001) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, serum GH-binding protein remained unchanged with GH versus placebo.

    In plain wordsIn GH-deficient adults, serum GH-binding protein did not change with GH compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeSerum GH-binding protein
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the placebo control period, serum IGF-I,LBM, and TBW increased (P < 0.001), whereas BF decreased (P < 0.001) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, individual body fat changes after 12 months of GH ranged from -12.5 to 4.3 kg.

    In plain wordsIn GH-deficient adults, body fat changes after 12 months of GH ranged from -12.5 to 4.3 kg.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedIndividual body fat change
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 12 monthsAs given in this study (human).

    Measurements

    Body fat change
    −12.5 to 4.3 kg
    individual changes

    Source sentences

    Summary
    After 12 months of GH treatment, the individual changes in BF ranged from -12.5 to 4.3 kg and from -4.5 to 10.1 kg in LBM.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  7. 07HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, individual lean body mass changes after 12 months of GH ranged from -4.5 to 10.1 kg.

    In plain wordsIn GH-deficient adults, lean body mass changes after 12 months of GH ranged from -4.5 to 10.1 kg.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedIndividual lean body mass change
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 12 monthsAs given in this study (human).

    Measurements

    Lean body mass change
    −4.5 to 10.1 kg
    individual changes

    Source sentences

    Summary
    After 12 months of GH treatment, the individual changes in BF ranged from -12.5 to 4.3 kg and from -4.5 to 10.1 kg in LBM.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  8. 08HumanNon-randomized trialOther

    In GH-treated GH-deficient adults, age was inversely correlated with the lean body mass increase (P < 0.05).

    In plain wordsIn GH-treated GH-deficient adults, older age was linked to a smaller lean body mass increase.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseAge and lean body mass response
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Age (P < 0.05) and baseline GHBP level (P < 0.01) were inversely correlated with the increase in LBM.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  9. 09HumanNon-randomized trialOther

    In GH-treated GH-deficient adults, baseline GHBP was inversely correlated with the lean body mass increase (P < 0.01).

    In plain wordsIn GH-treated GH-deficient adults, higher baseline GHBP was linked to a smaller lean body mass increase.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseBaseline GHBP and lean body mass response
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtime · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Age (P < 0.05) and baseline GHBP level (P < 0.01) were inversely correlated with the increase in LBM.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  10. 10HumanObservational studyEfficacy outcome

    In GH-deficient adults, the GH-induced IGF-I increase was greater in men than women (P < 0.01).

    In plain wordsIn GH-deficient adults, GH increased IGF-I more in men than women.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I increment by sex
    Study

    n = 68

    Comparator
    Women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtimeAs given in this study (human).

    Source sentences

    Summary
    The GH-induced increment in IGF-I and TBW was greater in men than in women (P < 0.01), whereas the decreases in BF were similar in men and women.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  11. 11HumanObservational studyEfficacy outcome

    In GH-deficient adults, the GH-induced total body water increase was greater in men than women (P < 0.01).

    In plain wordsIn GH-deficient adults, GH increased total body water more in men than women.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseTotal body water increment by sex
    Study

    n = 68

    Comparator
    Women
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtimeAs given in this study (human).

    Source sentences

    Summary
    The GH-induced increment in IGF-I and TBW was greater in men than in women (P < 0.01), whereas the decreases in BF were similar in men and women.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.
  12. 12HumanObservational studyEfficacy outcome

    In GH-deficient adults, body fat reductions with GH were similar in men and women.

    In plain wordsIn GH-deficient adults, GH reduced body fat similarly in men and women.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBody fat reduction by sex
    Study

    n = 68

    Comparator
    Women
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    target 12 micrograms/kg x day · sc daily at bedtimeAs given in this study (human).

    Source sentences

    Summary
    The GH-induced increment in IGF-I and TBW was greater in men than in women (P < 0.01), whereas the decreases in BF were similar in men and women.
    2 context sentences
    Summary · context
    Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized, double blind, placebo-controlled, 6-month period, followed by an open treatment period, thereby ensuring all patients 12 months of GH treatment.
    Summary · context
    Recombinant human GH was administered sc daily at bedtime, with a target dose of 12 micrograms/kg x day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.